Meir Medical Center Ethics Committee
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Uziel, Yosef
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Recruiting
3
58
Europe, Japan, RoW
Baricitinib, LY3009104, Tocilizumab
Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
10/25
10/25
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
12/30
12/30
Vishlitzky, Victor
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Not yet recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT04608305: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Completed
1/2
843
RoW
IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime), IIBR-100 low-dose (prime-boost), Saline Placebo (single), Saline Placebo (double), IIBR-100 medium-dose (prime-boost), IIBR-100 high-dose (prime-boost), IIBR-100 top-dose (prime-boost)
Israel Institute for Biological Research (IIBR)
Covid19
10/22
10/22

Download Options